UnknownPhase 3NCT00954174
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GOG Foundation
- Principal Investigator
- Matthew A PowellNRG Oncology
- Intervention
- Carboplatin(drug)
- Enrollment
- 637 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2009
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
- Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
- Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- John Muir Medical Center-Concord Campus, Concord, California, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
- Los Angeles County-USC Medical Center, Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00954174 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.